KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Short-term Investments: 2009-2017

Historic Short-term Investments for Jazz Pharmaceuticals (JAZZ) over the last 5 years, with Sep 2017 value amounting to $200.0 million.

  • Jazz Pharmaceuticals' Short-term Investments rose 236.60% to $200.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $200.0 million, marking a year-over-year increase of 236.60%. This contributed to the annual value of $60.0 million for FY2016, which is N/A change from last year.
  • According to the latest figures from Q3 2017, Jazz Pharmaceuticals' Short-term Investments is $200.0 million, which was up 150.00% from $80.0 million recorded in Q2 2017.
  • In the past 5 years, Jazz Pharmaceuticals' Short-term Investments ranged from a high of $200.0 million in Q3 2017 and a low of $764,000 during Q1 2016.
  • Its 2-year average for Short-term Investments is $72.7 million, with a median of $60.0 million in 2017.
  • Data for Jazz Pharmaceuticals' Short-term Investments shows a peak YoY surged of 7,753.40% (in 2017) over the last 5 years.
  • Quarterly analysis of 2 years shows Jazz Pharmaceuticals' Short-term Investments stood at $60.0 million in 2016, then surged by 236.60% to $200.0 million in 2017.
  • Its Short-term Investments was $200.0 million in Q3 2017, compared to $80.0 million in Q2 2017 and $60.0 million in Q1 2017.